Cargando…

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial

Detalles Bibliográficos
Autores principales:	Lago, Jamile, Fraga, Deborah, Guimarães, Luiz Henrique, Lago, Tainã, Silva, Yuri de Jesus, Lago, Ednaldo, Werneck, Guilherme L., Bacellar, Olívia, Carvalho, Edgar M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075408/ https://www.ncbi.nlm.nih.gov/pubmed/37018217 http://dx.doi.org/10.1371/journal.pntd.0011261

Ejemplares similares

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Clinical and histopathologic features of canine tegumentary leishmaniasis and the molecular characterization of Leishmania braziliensis in dogs
por: Lago, Jamile, et al.
Publicado: (2019)

Dogs Harbor Leishmania braziliensis and Participate in the Transmission Cycle of Human Tegumentary Leishmaniasis
por: Lago, Jamile, et al.
Publicado: (2023)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

Brief communication: Vitamin D serum levels in American tegumentary leishmaniasis from an endemic area in Northeast Brazil
por: Figueiredo, Lorena Pinheiro, et al.
Publicado: (2022)

Dynamics of American tegumentary leishmaniasis in a highly endemic region for Leishmania (Viannia) braziliensis infection in northeast Brazil
por: Silva, Juliana, et al.
Publicado: (2017)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis
por: Bashir, Uzma, et al.
Publicado: (2019)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2016)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis
por: Brito, Nayara C., et al.
Publicado: (2019)

Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis
por: Carvalho, Augusto M, et al.
Publicado: (2013)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
por: Ramalho, Dario Brock, et al.
Publicado: (2018)

The miRNA 361-3p, a Regulator of GZMB and TNF Is Associated With Therapeutic Failure and Longer Time Healing of Cutaneous Leishmaniasis Caused by L. (viannia) braziliensis
por: Lago, Tainã S., et al.
Publicado: (2018)

The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis☆
por: Oliveira, Walker Nonato, et al.
Publicado: (2014)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
por: Brahim, Lucia Regina, et al.
Publicado: (2017)

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil
por: Oliveira-Ribeiro, Carla, et al.
Publicado: (2021)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
por: Jamshidi, Sh, et al.
Publicado: (2011)

Diabetes Modifies the Clinic Presentation of Cutaneous Leishmaniasis
por: Lago, Alexsandro S, et al.
Publicado: (2020)

Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for Leishmania braziliensis: Clinical, Immunological and Parasitological Aspects
por: Guimarães, Luiz Henrique, et al.
Publicado: (2016)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
por: Barros, Andrea Barbieri, et al.
Publicado: (2014)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
por: Perez-Franco, Jairo E., et al.
Publicado: (2016)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)

Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)

IFN-γ Production to Leishmania Antigen Supplements the Leishmania Skin Test in Identifying Exposure to L. braziliensis Infection
por: Schnorr, Daniel, et al.
Publicado: (2012)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
por: Marques, Sílvio Alencar, et al.
Publicado: (2019)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: Ribeiro, Madelon Novato, et al.
Publicado: (2014)

Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
por: Khatami, Alireza, et al.
Publicado: (2013)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: LYRA, Marcelo Rosandiski, et al.
Publicado: (2016)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran
por: Aflatoonian, Mohammad Reza, et al.
Publicado: (2019)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
por: Berenguer, Diana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kfmldk1q57adoo5moid59v0n17